RxDoctor Payments Data

Divya Chauhan, MD

Allergy & Immunology · Denver, CONPI 1487920658

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,605 of the $4,233 with a category attached, or 61.6%. 11 manufacturers reported payments, led by AstraZeneca at 54.5% of the total. 2025 is the largest year on record at $1,110, 3.2 times the $348 reported in 2019.

$4,233in general payments, 2019–2025

Across 55 payments — averaging $76.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$676
  • Sanofi$537
  • Regeneron$427
  • Teva Pharmaceuticals USA, Inc.$121
  • Kaleo, Inc.$43
  • plus $120 from 5 others

What the payments were for

  • Consulting fees$1,62838%
  • Food & beverage$2,60562%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,233 in reported general payments places this provider in the 55th percentile of 89 allergy & immunology providers in Colorado.

See all allergy & immunology providers in Colorado

Medicare billing

Part B allowed, 2024
$470,660
Medicare patients
85
Services billed
13,978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fasenra PenBenralizumab26$149,421
Dupixent PenDupilumab19$71,891
DuleraMometasone/Formoterol21$16,917
Advair HfaFluticasone Propion/Salmeterol18$9,871
Mycophenolate Mofetil18$4,696
SymbicortBudesonide/Formoterol Fumarate11$4,284
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$3,663
Azelastine Hcl19$1,297
Ipratropium Bromide26$1,278
Fluticasone Propionate21$801
Montelukast Sodium25$378
Albuterol Sulfate HfaAlbuterol Sulfate13$306
Prednisone14$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort$2,307$4,28411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 89 allergy & immunology providers in Colorado.

Other allergy & immunology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →